CD36 antibody therapy has recently been shown to reduce cancer severity in preclinical models of human orthotopic oral cancer and prostate cancer patient-derived xenografts, supporting the clinical significance of antibody-based therapeutic targeting of CD36 [47,48]. The gene discussed is CD36; the disease is lip and oral cavity carcinoma.